- Home
- VTLE vs VSTM Comparison
VTLE vs VSTM Comparison
Compare VTLE & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$8.69
Company Overview
Basic Information| Metric | VTLE | VSTM |
|---|---|---|
| Founded | 2006 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 733.9M | 723.8M |
| IPO Year | 2011 | 2012 |
Fundamental Metrics
Financial Performance| Metric | VTLE | VSTM |
|---|---|---|
| Price | $17.92 | $8.69 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 9 |
| Target Price | ★ $25.78 | $13.38 |
| AVG Volume (30 Days) | 601.6K | ★ 2.1M |
| Earning Date | 11-03-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,897,003,000.00 | $13,379,000.00 |
| Revenue This Year | N/A | $183.10 |
| Revenue Next Year | N/A | $271.39 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 1.85 | ★ 33.79 |
| 52 Week Low | $12.30 | $3.46 |
| 52 Week High | $36.72 | $11.25 |
Technical Indicators
Market Signals| Indicator | VTLE | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 52.95 | 40.04 |
| Support Level | $17.79 | $9.13 |
| Resistance Level | $19.45 | $9.91 |
| Average True Range (ATR) | 0.65 | 0.55 |
| MACD | -0.03 | -0.19 |
| Stochastic Oscillator | 50.64 | 1.16 |
Price Performance
Historical Comparison VTLE
VSTM
About VTLE Vital Energy Inc. par value $0.01 per share
Vital Energy is an independent energy company. Its business is focused on the acquisition, exploration, and development of oil and natural gas properties in the Permian Basin of West Texas. The Company has identified one operating segment: exploration and production.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.